We are analyzing https://link.springer.com/article/10.1007/s11060-010-0192-y.

Title:
Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma | Journal of Neuro-Oncology
Description:
Even after gross tumor resection and combined radiochemotherapy, glioblastomas recur within a few months. Salvage therapy often consists of rechallenging with temozolomide in a dose-intensified schedule. Previously, low-dose metronomic temozolomide in combination with cyclo-oxigenase 2 inhibitors has had a beneficial effect as first-line treatment for glioblastoma. We report our experience with this procedure in recurrent glioblastomas after standard treatment. From June 2007 to April 2009, 28 patients with recurrent glioblastoma received continuous low-dose temozolomide of 10 mg/m2 twice daily and 200 mg celecoxib. Before therapy the recurrent tumor was resected in 19 of 28 patients. Microvessel density (MVD) was determined by immunohistochemistry in 19 patients, and MGMT promoter methylation status, using the pyrosequencing method, was determined in 17 patients. In 14/28 patients, positron emission tomography with [F-18]-fluoroethyl)-l-tyrosine (FET-PET) was performed. Tumor progression was defined by the Macdonald criteria on MRI every 8–12 weeks or by clinical deterioration. The median time to progression was 4.2 months. Progression-free survival (PFS) after 6 months was 43%. Except for a lymphopenia in one patient, there was no grade 3 or 4 toxicity. PFS did not correlate with MVD or MGMT status. A high FET uptake correlated with tumor control after 6 months under therapy (P = 0.041, t-test). Low-dose continuous temozolomide in combination with celecoxib seems to have activity in recurrent glioblastoma without relevant toxicity. High FET uptake correlated with a better outcome under metronomic therapy.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure how the site profits.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

article, google, scholar, pubmed, glioblastoma, cas, temozolomide, recurrent, patients, cancer, chemotherapy, therapy, glioma, oncol, lowdose, study, access, weller, med, clin, neurooncol, berlin, privacy, cookies, content, journal, continuous, clinical, stockhammer, koch, combination, mgmt, status, phase, wick, publish, search, celecoxib, tuettenberg, vajkoczy, tumor, months, metronomic, treatment, multiforme, recurrence, malignant, author, pet, nucl,

Topics {✒️}

f-18-fluoro-ethyl-tyrosin uptake o6-methylguanine-dna methyltransferase status experimental drug-resistant cancer month download article/chapter continuous low-dose chemotherapy o6-alkylguanine-dna alkyltransferase methylguanine-dna methyltransferase status low-dose continuous temozolomide continuous low-dose temozolomide low-dose metronomic temozolomide 18f-fluoroethyl-l-tyrosine pet progressive mgmt-methylated glioblastoma recurrent high-grade gliomas neoplastic brain components anti-angiogenic chemotherapy low-dose chemotherapy full article pdf privacy choices/manage cookies phase ii study dose-intensified schedule positron emission tomography l-tyrosine pet l-tyrosine pet mgmt gene silencing neuro-oncology aims low-grade glioma van landeghem fk contrast-enhancing gliomas phase ii studies recurrent human glioblastomas european economic area fet-pet brandes aa schold sc jr yung wk ppar-gamma agonists theodor-kutzer-ufer 1–3 conditions privacy policy article stockhammer cyclo-oxigenase 2 inhibitors alternating weekly regimen chemotherapy improves efficacy clinical outcome /ii trial metronomic chemotherapy gross tumor resection article journal accepting optional cookies cristiane blechschmidt progression-free survival

Questions {❓}

Hau P, Baumgart U, Pfeifer K, Bock A, Jauch T, Dietrich J, Fabel K, Grauer O, Wismeth C, Klinkhammer-Schalke M, Allgauer M, Schuierer G, Koch H, Schlaier J, Ulrich W, Brawanski A, Bogdahn U, Steinbrecher A (2003) Salvage therapy in patients with glioblastoma: is there any benefit?
Koch D, Wick W (2006) Higher dosing of temozolomide?
Tihan T, Barletta J, Parney I, Lamborn K, Sneed PK, Chang S (2006) Prognostic value of detecting recurrent glioblastoma multiforme in surgical specimens from patients after radiotherapy: should pathology evaluation alter treatment decisions?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma
         description:Even after gross tumor resection and combined radiochemotherapy, glioblastomas recur within a few months. Salvage therapy often consists of rechallenging with temozolomide in a dose-intensified schedule. Previously, low-dose metronomic temozolomide in combination with cyclo-oxigenase 2 inhibitors has had a beneficial effect as first-line treatment for glioblastoma. We report our experience with this procedure in recurrent glioblastomas after standard treatment. From June 2007 to April 2009, 28 patients with recurrent glioblastoma received continuous low-dose temozolomide of 10 mg/m2 twice daily and 200 mg celecoxib. Before therapy the recurrent tumor was resected in 19 of 28 patients. Microvessel density (MVD) was determined by immunohistochemistry in 19 patients, and MGMT promoter methylation status, using the pyrosequencing method, was determined in 17 patients. In 14/28 patients, positron emission tomography with [F-18]-fluoroethyl)-l-tyrosine (FET-PET) was performed. Tumor progression was defined by the Macdonald criteria on MRI every 8–12 weeks or by clinical deterioration. The median time to progression was 4.2 months. Progression-free survival (PFS) after 6 months was 43%. Except for a lymphopenia in one patient, there was no grade 3 or 4 toxicity. PFS did not correlate with MVD or MGMT status. A high FET uptake correlated with tumor control after 6 months under therapy (P = 0.041, t-test). Low-dose continuous temozolomide in combination with celecoxib seems to have activity in recurrent glioblastoma without relevant toxicity. High FET uptake correlated with a better outcome under metronomic therapy.
         datePublished:2010-05-06T00:00:00Z
         dateModified:2010-05-06T00:00:00Z
         pageStart:407
         pageEnd:415
         sameAs:https://doi.org/10.1007/s11060-010-0192-y
         keywords:
            Glioblastoma
            Recurrence
            Anti-angiogenesis
            Metronomic
            FET-PET
            MGMT
            Oncology
            Neurology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11060-010-0192-y/MediaObjects/11060_2010_192_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11060-010-0192-y/MediaObjects/11060_2010_192_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11060-010-0192-y/MediaObjects/11060_2010_192_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11060-010-0192-y/MediaObjects/11060_2010_192_Fig4_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11060-010-0192-y/MediaObjects/11060_2010_192_Fig5_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11060-010-0192-y/MediaObjects/11060_2010_192_Fig6_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11060-010-0192-y/MediaObjects/11060_2010_192_Fig7_HTML.gif
         isPartOf:
            name:Journal of Neuro-Oncology
            issn:
               1573-7373
               0167-594X
            volumeNumber:100
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Florian Stockhammer
               affiliation:
                     name:Charité Universitätsmedizin Berlin
                     address:
                        name:Department of Neurosurgery, Charité Universitätsmedizin Berlin, Berlin, Germany
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Martin Misch
               affiliation:
                     name:Charité Universitätsmedizin Berlin
                     address:
                        name:Department of Neurosurgery, Charité Universitätsmedizin Berlin, Berlin, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Arend Koch
               affiliation:
                     name:Charité Universitätsmedizin Berlin
                     address:
                        name:Department of Neuropathology, Charité Universitätsmedizin Berlin, Berlin, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Marcus Czabanka
               affiliation:
                     name:Charité Universitätsmedizin Berlin
                     address:
                        name:Department of Neurosurgery, Charité Universitätsmedizin Berlin, Berlin, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Michail Plotkin
               affiliation:
                     name:Charité Universitätsmedizin Berlin
                     address:
                        name:Department of Nuclear-Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Cristiane Blechschmidt
               affiliation:
                     name:Charité Universitätsmedizin Berlin
                     address:
                        name:Department of Neuropathology, Charité Universitätsmedizin Berlin, Berlin, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jochen Tuettenberg
               affiliation:
                     name:Universitätsmedizin Mannheim, University of Heidelberg
                     address:
                        name:Department of Neurosurgery, Universitätsmedizin Mannheim, University of Heidelberg, Mannheim, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Peter Vajkoczy
               affiliation:
                     name:Charité Universitätsmedizin Berlin
                     address:
                        name:Department of Neurosurgery, Charité Universitätsmedizin Berlin, Berlin, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma
      description:Even after gross tumor resection and combined radiochemotherapy, glioblastomas recur within a few months. Salvage therapy often consists of rechallenging with temozolomide in a dose-intensified schedule. Previously, low-dose metronomic temozolomide in combination with cyclo-oxigenase 2 inhibitors has had a beneficial effect as first-line treatment for glioblastoma. We report our experience with this procedure in recurrent glioblastomas after standard treatment. From June 2007 to April 2009, 28 patients with recurrent glioblastoma received continuous low-dose temozolomide of 10 mg/m2 twice daily and 200 mg celecoxib. Before therapy the recurrent tumor was resected in 19 of 28 patients. Microvessel density (MVD) was determined by immunohistochemistry in 19 patients, and MGMT promoter methylation status, using the pyrosequencing method, was determined in 17 patients. In 14/28 patients, positron emission tomography with [F-18]-fluoroethyl)-l-tyrosine (FET-PET) was performed. Tumor progression was defined by the Macdonald criteria on MRI every 8–12 weeks or by clinical deterioration. The median time to progression was 4.2 months. Progression-free survival (PFS) after 6 months was 43%. Except for a lymphopenia in one patient, there was no grade 3 or 4 toxicity. PFS did not correlate with MVD or MGMT status. A high FET uptake correlated with tumor control after 6 months under therapy (P = 0.041, t-test). Low-dose continuous temozolomide in combination with celecoxib seems to have activity in recurrent glioblastoma without relevant toxicity. High FET uptake correlated with a better outcome under metronomic therapy.
      datePublished:2010-05-06T00:00:00Z
      dateModified:2010-05-06T00:00:00Z
      pageStart:407
      pageEnd:415
      sameAs:https://doi.org/10.1007/s11060-010-0192-y
      keywords:
         Glioblastoma
         Recurrence
         Anti-angiogenesis
         Metronomic
         FET-PET
         MGMT
         Oncology
         Neurology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11060-010-0192-y/MediaObjects/11060_2010_192_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11060-010-0192-y/MediaObjects/11060_2010_192_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11060-010-0192-y/MediaObjects/11060_2010_192_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11060-010-0192-y/MediaObjects/11060_2010_192_Fig4_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11060-010-0192-y/MediaObjects/11060_2010_192_Fig5_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11060-010-0192-y/MediaObjects/11060_2010_192_Fig6_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11060-010-0192-y/MediaObjects/11060_2010_192_Fig7_HTML.gif
      isPartOf:
         name:Journal of Neuro-Oncology
         issn:
            1573-7373
            0167-594X
         volumeNumber:100
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Florian Stockhammer
            affiliation:
                  name:Charité Universitätsmedizin Berlin
                  address:
                     name:Department of Neurosurgery, Charité Universitätsmedizin Berlin, Berlin, Germany
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Martin Misch
            affiliation:
                  name:Charité Universitätsmedizin Berlin
                  address:
                     name:Department of Neurosurgery, Charité Universitätsmedizin Berlin, Berlin, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Arend Koch
            affiliation:
                  name:Charité Universitätsmedizin Berlin
                  address:
                     name:Department of Neuropathology, Charité Universitätsmedizin Berlin, Berlin, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Marcus Czabanka
            affiliation:
                  name:Charité Universitätsmedizin Berlin
                  address:
                     name:Department of Neurosurgery, Charité Universitätsmedizin Berlin, Berlin, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Michail Plotkin
            affiliation:
                  name:Charité Universitätsmedizin Berlin
                  address:
                     name:Department of Nuclear-Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Cristiane Blechschmidt
            affiliation:
                  name:Charité Universitätsmedizin Berlin
                  address:
                     name:Department of Neuropathology, Charité Universitätsmedizin Berlin, Berlin, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jochen Tuettenberg
            affiliation:
                  name:Universitätsmedizin Mannheim, University of Heidelberg
                  address:
                     name:Department of Neurosurgery, Universitätsmedizin Mannheim, University of Heidelberg, Mannheim, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Peter Vajkoczy
            affiliation:
                  name:Charité Universitätsmedizin Berlin
                  address:
                     name:Department of Neurosurgery, Charité Universitätsmedizin Berlin, Berlin, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Journal of Neuro-Oncology
      issn:
         1573-7373
         0167-594X
      volumeNumber:100
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Charité Universitätsmedizin Berlin
      address:
         name:Department of Neurosurgery, Charité Universitätsmedizin Berlin, Berlin, Germany
         type:PostalAddress
      name:Charité Universitätsmedizin Berlin
      address:
         name:Department of Neurosurgery, Charité Universitätsmedizin Berlin, Berlin, Germany
         type:PostalAddress
      name:Charité Universitätsmedizin Berlin
      address:
         name:Department of Neuropathology, Charité Universitätsmedizin Berlin, Berlin, Germany
         type:PostalAddress
      name:Charité Universitätsmedizin Berlin
      address:
         name:Department of Neurosurgery, Charité Universitätsmedizin Berlin, Berlin, Germany
         type:PostalAddress
      name:Charité Universitätsmedizin Berlin
      address:
         name:Department of Nuclear-Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany
         type:PostalAddress
      name:Charité Universitätsmedizin Berlin
      address:
         name:Department of Neuropathology, Charité Universitätsmedizin Berlin, Berlin, Germany
         type:PostalAddress
      name:Universitätsmedizin Mannheim, University of Heidelberg
      address:
         name:Department of Neurosurgery, Universitätsmedizin Mannheim, University of Heidelberg, Mannheim, Germany
         type:PostalAddress
      name:Charité Universitätsmedizin Berlin
      address:
         name:Department of Neurosurgery, Charité Universitätsmedizin Berlin, Berlin, Germany
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Florian Stockhammer
      affiliation:
            name:Charité Universitätsmedizin Berlin
            address:
               name:Department of Neurosurgery, Charité Universitätsmedizin Berlin, Berlin, Germany
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Martin Misch
      affiliation:
            name:Charité Universitätsmedizin Berlin
            address:
               name:Department of Neurosurgery, Charité Universitätsmedizin Berlin, Berlin, Germany
               type:PostalAddress
            type:Organization
      name:Arend Koch
      affiliation:
            name:Charité Universitätsmedizin Berlin
            address:
               name:Department of Neuropathology, Charité Universitätsmedizin Berlin, Berlin, Germany
               type:PostalAddress
            type:Organization
      name:Marcus Czabanka
      affiliation:
            name:Charité Universitätsmedizin Berlin
            address:
               name:Department of Neurosurgery, Charité Universitätsmedizin Berlin, Berlin, Germany
               type:PostalAddress
            type:Organization
      name:Michail Plotkin
      affiliation:
            name:Charité Universitätsmedizin Berlin
            address:
               name:Department of Nuclear-Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany
               type:PostalAddress
            type:Organization
      name:Cristiane Blechschmidt
      affiliation:
            name:Charité Universitätsmedizin Berlin
            address:
               name:Department of Neuropathology, Charité Universitätsmedizin Berlin, Berlin, Germany
               type:PostalAddress
            type:Organization
      name:Jochen Tuettenberg
      affiliation:
            name:Universitätsmedizin Mannheim, University of Heidelberg
            address:
               name:Department of Neurosurgery, Universitätsmedizin Mannheim, University of Heidelberg, Mannheim, Germany
               type:PostalAddress
            type:Organization
      name:Peter Vajkoczy
      affiliation:
            name:Charité Universitätsmedizin Berlin
            address:
               name:Department of Neurosurgery, Charité Universitätsmedizin Berlin, Berlin, Germany
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Neurosurgery, Charité Universitätsmedizin Berlin, Berlin, Germany
      name:Department of Neurosurgery, Charité Universitätsmedizin Berlin, Berlin, Germany
      name:Department of Neuropathology, Charité Universitätsmedizin Berlin, Berlin, Germany
      name:Department of Neurosurgery, Charité Universitätsmedizin Berlin, Berlin, Germany
      name:Department of Nuclear-Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany
      name:Department of Neuropathology, Charité Universitätsmedizin Berlin, Berlin, Germany
      name:Department of Neurosurgery, Universitätsmedizin Mannheim, University of Heidelberg, Mannheim, Germany
      name:Department of Neurosurgery, Charité Universitätsmedizin Berlin, Berlin, Germany
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(119)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Hammer.js
Prism.js

CDN Services {📦}

Crossref

4.38s.

LINK . SPRINGER . COM {}